Quibim, a company with its headquarters in Valencia, Spain, is a global leader in whole-body medical imaging analysis. Quibim products are used worldwide by leading research teams. Partners use Quibim Precision®, a whole-body imaging ecosystem, for a wide range of applications from detecting a disease to tracking the efficacy of novel treatments. Quibim follows an AI-first approach to help detect pathologies across every body part and imaging modality, using quantitative imaging biomarkers. 

Quibim was founded by Dr. Ángel Alberich-Bayarri and Prof. Luis Marti-Bonmati, two innovators at the forefront of medical imaging. They established the process for the development of biomarkers, adopted in 2013 by the European Society of Radiology (ESR) as the official industry standard. They again set a benchmark when, in March 2020, Quibim became the main AI platform for screening for COVID-19 across Europe. Shortly after, the Radiological Society of North America (RSNA), with more than 52,000 members from 153 countries, joined the initiative with the goal of creating a global medical repository of COVID-19 cases, with the European arm running on Quibim Precision®. 

Before founding Quibim, Dr. Ángel Alberich-Bayarri worked first as a telecom engineer for the University of Valencia and then for various R&D projects, for two hospitals and for SEDIA Investiga. He also worked for the Grupo Universitario Quiron in R&D. Dr. Ángel Alberich-Bayarri holds a PhD in Engineering and Biomedical Engineering one in from the Universitat Politècnica de València. He is Quibim's CEO.